Tudor Investment Corp ET AL raised its stake in shares of Geron Corporation (NASDAQ:GERN) by 12.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 52,369 shares of the biopharmaceutical company’s stock after buying an additional 5,669 shares during the period. Tudor Investment Corp ET AL’s holdings in Geron Corporation were worth $119,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Geron Corporation by 26.5% in the first quarter. Bank of America Corp DE now owns 65,403 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 13,698 shares in the last quarter. KCG Holdings Inc. raised its stake in shares of Geron Corporation by 132.5% in the first quarter. KCG Holdings Inc. now owns 167,755 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 95,615 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Geron Corporation during the first quarter valued at approximately $820,000. Geode Capital Management LLC raised its stake in shares of Geron Corporation by 11.0% in the first quarter. Geode Capital Management LLC now owns 1,212,214 shares of the biopharmaceutical company’s stock valued at $2,751,000 after buying an additional 120,222 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Geron Corporation by 7.6% in the first quarter. Vanguard Group Inc. now owns 7,112,183 shares of the biopharmaceutical company’s stock valued at $16,145,000 after buying an additional 502,485 shares during the last quarter. 38.22% of the stock is owned by institutional investors.
Geron Corporation (NASDAQ:GERN) opened at 2.03 on Friday. Geron Corporation has a 12 month low of $1.81 and a 12 month high of $3.15. The firm’s market cap is $323.20 million. The firm’s 50-day moving average is $2.56 and its 200-day moving average is $2.48.
Geron Corporation (NASDAQ:GERN) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. Geron Corporation had a negative return on equity of 21.30% and a negative net margin of 433.72%. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.38 million. During the same period last year, the company earned ($0.05) earnings per share. The business’s quarterly revenue was down 19.0% on a year-over-year basis. Equities analysts expect that Geron Corporation will post ($0.18) earnings per share for the current year.
Several brokerages have issued reports on GERN. BidaskClub downgraded shares of Geron Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research downgraded shares of Geron Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Geron Corporation in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $3.88.
About Geron Corporation
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
What are top analysts saying about Geron Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron Corporation and related companies.